SMM: Taking the narrow over the wide path https://t.co/jPBsZo5Dxv This is a plea (and not a criticism) to #msmm#myeloma community to heavily invest in genomic, immunogenomic & biomarkers studies to generate better classifiers of risk of progression or redefine SMM as MGUS or MM
Targeted depletion of TRBV9+ T cells induces remission in a single ankylosing spondylitis patient, with significant improvements in functional and mobility metrics #Immunotherapy#AnkylosingSpondylitis https://t.co/KXc0EL7nHv
What #Tcells are hiding in your #SingleCell data?
Plenty of existing tools that claim to address this challenge, but are they consistent? Our review is now out in @FrontImmunol , with thanks to @czi for funding!
https://t.co/sa7akF93Mg
@C_Askenberg Vi kunne hatt en konstruktiv diskusjon om vi legger inn for mange pasienter som har lav risiko for alvorlig sykdom. Men at vi kan legge inn færre (som må være målet?) uten noen risiko, det blir bare useriøst
Congrats to brilliant postdoc Zsofia Fôldvari on her paper outlining a much-needed strategy to select safe T-cell receptors! https://t.co/8HJRLYkpBZ A wonderful collaboration with M. Leisegang and team at @ChariteBerlin & our team @UniOslo_MED / @Oslounivsykehus . @Nature_NPJ
4 orals, 6 posters, 1 educational and 2 Abstract achievement awards at #ASH22 from the @iStopMM study (w/9 different presenters)!
We are ridiculously excited to share our results after screening >75,000 Icelanders for MGUS.
And we are just beginning!
#mmsm 🧵Abstracts:
Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10
Feasibility of clinical whole genome and transcriptome sequencing (WGTS) in oncology. A 🧵 on our latest study published in Nature Communications today:https://t.co/6007GkYDAc